" class="no-js "lang="en-US"> Rahul Doshi - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rahul Doshi

Rahul Doshi

About Rahul Doshi

Dr. Doshi draws from a wide range of possible treatments to customize his approach for each individual patient. He uses uniquely tailored therapy, which allows him to evolve treatment strategies and develop ongoing partnerships with his patients.

Related Story

Cardiovascular

 Abbott Receives FDA Approval for Aveir™ Vr Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms | Pharmtech Focus

Abbott Receives FDA Approval for Aveir™ Vr Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms

April 5 2022

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved […]